JP2001526232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001526232A5 JP2001526232A5 JP2000525116A JP2000525116A JP2001526232A5 JP 2001526232 A5 JP2001526232 A5 JP 2001526232A5 JP 2000525116 A JP2000525116 A JP 2000525116A JP 2000525116 A JP2000525116 A JP 2000525116A JP 2001526232 A5 JP2001526232 A5 JP 2001526232A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- oratidine
- antihistamine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 5
- 230000001387 anti-histamine Effects 0.000 description 5
- 239000000739 antihistaminic agent Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical group C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 4
- 229960001271 desloratadine Drugs 0.000 description 4
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 3
- 229960001803 cetirizine Drugs 0.000 description 3
- 229960001971 ebastine Drugs 0.000 description 3
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 3
- 229950003420 efletirizine Drugs 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 229960003592 fexofenadine Drugs 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
- 229960005127 montelukast Drugs 0.000 description 3
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229960004583 pranlukast Drugs 0.000 description 2
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- -1 (R) -3 (3- (2- (2,3-dichlorothieno [3,2-b] pyridin-5-yl)-(E) -ethenyl) phenyl) -3 -(2- (1-hydroxy-1-methylethyl) phenyl) propyl Chemical group 0.000 description 1
- AOPATQAZIRXNOX-UHFFFAOYSA-N 2-(1-methylcyclopropyl)acetic acid Chemical compound OC(=O)CC1(C)CC1 AOPATQAZIRXNOX-UHFFFAOYSA-N 0.000 description 1
- PSILZZNMGXTOOP-UHFFFAOYSA-N 2-[2-[[2-(4-tert-butyl-1,3-thiazol-2-yl)-1-benzofuran-5-yl]oxymethyl]phenyl]acetic acid Chemical compound CC(C)(C)C1=CSC(C=2OC3=CC=C(OCC=4C(=CC=CC=4)CC(O)=O)C=C3C=2)=N1 PSILZZNMGXTOOP-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical group COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical group C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical group CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6863897P | 1997-12-23 | 1997-12-23 | |
| US7863898P | 1998-03-19 | 1998-03-19 | |
| US60/078,638 | 1998-03-19 | ||
| US60/068,638 | 1998-03-19 | ||
| PCT/US1998/026223 WO1999032125A1 (en) | 1997-12-23 | 1998-12-21 | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010291255A Division JP2011068679A (ja) | 1997-12-23 | 2010-12-27 | 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001526232A JP2001526232A (ja) | 2001-12-18 |
| JP2001526232A5 true JP2001526232A5 (https=) | 2006-02-09 |
Family
ID=26749192
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000525116A Pending JP2001526232A (ja) | 1997-12-23 | 1998-12-21 | 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物 |
| JP2010291255A Withdrawn JP2011068679A (ja) | 1997-12-23 | 2010-12-27 | 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010291255A Withdrawn JP2011068679A (ja) | 1997-12-23 | 2010-12-27 | 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1041990B1 (https=) |
| JP (2) | JP2001526232A (https=) |
| KR (1) | KR100737710B1 (https=) |
| CN (1) | CN1283115A (https=) |
| AR (1) | AR017224A1 (https=) |
| AT (1) | ATE331522T1 (https=) |
| AU (1) | AU758771B2 (https=) |
| BR (1) | BR9814417A (https=) |
| CA (1) | CA2315721C (https=) |
| CO (1) | CO4980868A1 (https=) |
| CZ (1) | CZ301349B6 (https=) |
| DE (1) | DE69835103T2 (https=) |
| DK (1) | DK1041990T3 (https=) |
| ES (1) | ES2263229T3 (https=) |
| HU (1) | HUP0101369A3 (https=) |
| ID (1) | ID26390A (https=) |
| IL (1) | IL136461A0 (https=) |
| MY (1) | MY121744A (https=) |
| NO (1) | NO20003288L (https=) |
| NZ (1) | NZ520907A (https=) |
| PE (1) | PE20000126A1 (https=) |
| PL (1) | PL193131B1 (https=) |
| PT (1) | PT1041990E (https=) |
| SA (1) | SA99200013B1 (https=) |
| SK (1) | SK286103B6 (https=) |
| WO (1) | WO1999032125A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257704T1 (de) | 1992-09-03 | 2004-01-15 | Sepracor Inc | Pharmazeutische zusammensetzungen enthaltend norastemizol. |
| US6303632B1 (en) | 1992-09-03 | 2001-10-16 | Sepracor Inc. | Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients |
| US7214683B1 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
| US7211582B1 (en) | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
| US6194431B1 (en) | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US6248308B1 (en) * | 1998-04-14 | 2001-06-19 | Sepracor Inc. | Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma |
| IT1303671B1 (it) | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
| EP1000623A1 (en) * | 1998-09-29 | 2000-05-17 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Use of epinastine as antitussivum |
| WO2000018399A1 (fr) * | 1998-09-30 | 2000-04-06 | Ono Pharmaceutical Co., Ltd. | Agents preventifs et/ou therapeutiques contre la sinusite |
| US20020198246A1 (en) | 1998-09-30 | 2002-12-26 | Ono Pharmaceutical Co., Ltd. | Agent for preventing and/or treating sinusitis |
| EP1251851A1 (en) * | 2000-02-03 | 2002-10-30 | Schering Corporation | Treating allergic and inflammatory conditions |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| JP2002087963A (ja) * | 2000-09-08 | 2002-03-27 | Nippon Boehringer Ingelheim Co Ltd | 直接打錠により製造されたエピナスチン含有錠剤 |
| US20020094345A1 (en) | 2000-10-06 | 2002-07-18 | Sara Abelaira | Pharmaceutical compositions containing epinastine and pseudoephedrine |
| PE20020324A1 (es) * | 2000-10-06 | 2002-06-18 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina |
| JP4074427B2 (ja) | 2000-12-18 | 2008-04-09 | 株式会社栃木臨床病理研究所 | 子宮内膜症の予防又は治療薬 |
| US20020198228A1 (en) * | 2001-04-03 | 2002-12-26 | Kaura Sita R. | Composition and method for the treatment of respiratory desease |
| BR0210534A (pt) * | 2001-06-20 | 2004-06-22 | Schering Corp | Anti-histaminas para o tratamento de congestão nasal e obstrução nasal |
| GB0115181D0 (en) * | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
| DE60232445D1 (de) | 2001-06-28 | 2009-07-09 | Ucb Farchim Sa | Cetirizin und pseudoephedrin enthaltende tablette |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| WO2003101434A2 (en) * | 2001-12-21 | 2003-12-11 | Sampad Bhattacharya | Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor |
| BR0306329A (pt) * | 2002-05-29 | 2005-04-26 | Aventis Pharmaceuticals Holdin | Método de tratamento de asma |
| AU2003249881A1 (en) * | 2002-07-02 | 2004-01-23 | Ucb Farchim S.A. | Diarylmethylpiperazines as prophylactic or therapeutic agents for viral myocarditis |
| DE60322577D1 (de) * | 2002-12-06 | 2008-09-11 | Ucb Farchim Sa | Tablette enthaltend efletirizin und pseudoephedrin |
| WO2004087095A2 (es) * | 2003-03-31 | 2004-10-14 | Osmotica Costa Rica, Sociedad Anonima | Dispositivo osmótico que contiene zafirlukast y un antagonista h1 |
| EP1468696A1 (en) * | 2003-04-17 | 2004-10-20 | Boehringer Ingelheim International GmbH | Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases |
| WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
| JP2007530481A (ja) * | 2004-03-24 | 2007-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エピナスチン及び１又は２以上の追加のミネラル又は１又は２以上の生薬のコンビネーションを含む皮膚疾患の治療用医薬組成物 |
| TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
| RU2429844C1 (ru) * | 2010-04-12 | 2011-09-27 | Вячеслав Михайлович Провоторов | Способ лечения мужчин, больных бронхиальной астмой с ранним приобретенным андрогенодефицитом |
| KR20130050952A (ko) * | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| JP6051378B2 (ja) * | 2011-05-02 | 2016-12-27 | 国立大学法人 熊本大学 | 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法 |
| KR20130009553A (ko) * | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| WO2013058527A2 (ko) * | 2011-10-18 | 2013-04-25 | 주식회사 네비팜 | 류코트리엔 길항제와 에피나스틴의 복합제제 |
| KR101278572B1 (ko) * | 2011-10-18 | 2013-06-25 | 주식회사 네비팜 | 류코트리엔 길항제와 에피나스틴의 복합제제 |
| WO2014164285A2 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| MX382776B (es) | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| US9636318B2 (en) * | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| KR102356601B1 (ko) | 2014-06-10 | 2022-01-27 | 지엘팜텍주식회사 | 슈도에페드린을 함유하는 방출조절 펠렛 조성물 |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| US9981039B2 (en) | 2015-05-29 | 2018-05-29 | Accolade Pharma Llc | Composition, its preparation and method of use in treating skin disorders |
| CN109152754A (zh) * | 2016-05-17 | 2019-01-04 | 拥护者生物技术有限公司 | 用于治疗/预防鼻充血的羧酸 |
| EP3458042A1 (en) * | 2016-05-17 | 2019-03-27 | Proponent Biotech GmbH | Carboxylic acids for treating/preventing a skin disease |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| WO2026038890A1 (ko) * | 2024-08-13 | 2026-02-19 | 광주과학기술원 | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4662880A (en) * | 1986-03-14 | 1987-05-05 | Alza Corporation | Pseudoephedrine, brompheniramine therapy |
| US4810502A (en) * | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US5276044A (en) * | 1991-08-14 | 1994-01-04 | Allergan, Inc. | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions |
| DE59310252D1 (de) * | 1992-02-05 | 2002-01-24 | Boehringer Ingelheim Pharma | Neue Amiderivate, ihre Herstellung und Verwendung als Arzneimittel mit LTB4-antagonistischer Wirkung |
| DE4203201A1 (de) * | 1992-02-05 | 1993-08-12 | Boehringer Ingelheim Kg | Neue amidinderivate, ihre herstellung und verwendung |
| US5270324A (en) * | 1992-04-10 | 1993-12-14 | Merck Frosst Canada, Inc. | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| JPH08325265A (ja) * | 1995-05-29 | 1996-12-10 | Fujisawa Pharmaceut Co Ltd | チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物 |
| EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
| EE9800234A (et) * | 1996-02-08 | 1998-12-15 | Merck & Co., Inc. | Ravimeetod ja farmatseutiline kompositsioon |
| BR9709650A (pt) * | 1996-06-04 | 1999-08-10 | Procter & Gamble | Aerosol nasal contendo um esteróide intransal e um anti-histamínico |
| US5900421A (en) * | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
| JP2001524108A (ja) * | 1997-04-30 | 2001-11-27 | ワーナー−ランバート・カンパニー | 局所経鼻抗炎症組成物 |
-
1998
- 1998-12-21 PL PL341343A patent/PL193131B1/pl not_active IP Right Cessation
- 1998-12-21 AR ARP980106566A patent/AR017224A1/es not_active Application Discontinuation
- 1998-12-21 BR BR9814417-0A patent/BR9814417A/pt not_active Application Discontinuation
- 1998-12-21 CZ CZ20002198A patent/CZ301349B6/cs not_active IP Right Cessation
- 1998-12-21 ID IDW20001217A patent/ID26390A/id unknown
- 1998-12-21 DE DE69835103T patent/DE69835103T2/de not_active Expired - Lifetime
- 1998-12-21 NZ NZ520907A patent/NZ520907A/en not_active IP Right Cessation
- 1998-12-21 MY MYPI98005791A patent/MY121744A/en unknown
- 1998-12-21 ES ES98963828T patent/ES2263229T3/es not_active Expired - Lifetime
- 1998-12-21 DK DK98963828T patent/DK1041990T3/da active
- 1998-12-21 CA CA002315721A patent/CA2315721C/en not_active Expired - Fee Related
- 1998-12-21 SK SK897-2000A patent/SK286103B6/sk not_active IP Right Cessation
- 1998-12-21 PT PT98963828T patent/PT1041990E/pt unknown
- 1998-12-21 KR KR1020007006986A patent/KR100737710B1/ko not_active Expired - Fee Related
- 1998-12-21 CN CN98812638A patent/CN1283115A/zh active Pending
- 1998-12-21 EP EP98963828A patent/EP1041990B1/en not_active Expired - Lifetime
- 1998-12-21 IL IL13646198A patent/IL136461A0/xx not_active IP Right Cessation
- 1998-12-21 HU HU0101369A patent/HUP0101369A3/hu unknown
- 1998-12-21 AU AU19071/99A patent/AU758771B2/en not_active Ceased
- 1998-12-21 JP JP2000525116A patent/JP2001526232A/ja active Pending
- 1998-12-21 AT AT98963828T patent/ATE331522T1/de active
- 1998-12-21 WO PCT/US1998/026223 patent/WO1999032125A1/en not_active Ceased
- 1998-12-22 CO CO98075939A patent/CO4980868A1/es unknown
- 1998-12-22 PE PE1998001265A patent/PE20000126A1/es not_active Application Discontinuation
-
1999
- 1999-04-20 SA SA99200013A patent/SA99200013B1/ar unknown
-
2000
- 2000-06-22 NO NO20003288A patent/NO20003288L/no not_active Application Discontinuation
-
2010
- 2010-12-27 JP JP2010291255A patent/JP2011068679A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001526232A5 (https=) | ||
| EP1041990B1 (en) | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine | |
| JP2008297311A (ja) | 気道疾患の処置のためのプレコナリルを含む薬学的処方物 | |
| RU2007104095A (ru) | Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств | |
| JP2008509143A5 (https=) | ||
| JP2009526063A (ja) | 医薬製剤 | |
| CA2328073A1 (en) | Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition | |
| JP2008540356A (ja) | 薬物乱用の治療方法 | |
| CN101588797A (zh) | 带有最小化副作用包括减轻肝毒性的对乙酰氨基酚组合物 | |
| JP2009526062A (ja) | 薬学的処方物 | |
| US20120149730A1 (en) | Methods and compositions using racemic, (r)-, and (s)-fexofenadine in combination with leukotriene inhibitors | |
| US6423721B1 (en) | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines | |
| WO2001032166A1 (en) | NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST | |
| US6372197B1 (en) | Methods and compositions using norastemizole in combination with leukotriene inhibitors | |
| JP4318899B2 (ja) | 抗感冒剤 | |
| US20220031687A1 (en) | Synergic pharmaceutical combination of a leukotriene-receptor antagonist and an inverse agonist of histamine hi | |
| MXPA00006254A (en) | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine | |
| HK1027502B (en) | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine | |
| JP2010111666A (ja) | セチリジンを含有する鎮咳及び／又は去痰のための医薬組成物 |